Nobivac Myxo-RHD


live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009

This medicine is now withdrawn from use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 12/09/2023

Authorisation details

Product details
Nobivac Myxo-RHD
Agency product number
Active substance
live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009
International non-proprietary name (INN) or common name
live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer

Product information

18/03/2021 Nobivac Myxo-RHD - EMEA/V/C/002004 - IG/1348

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

For active immunisation of rabbits from five weeks of age onwards to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease.

Onset of immunity: 3 weeks.

Duration of immunity: 1 year.

Assessment history

How useful was this page?

Add your rating